Zoetis Inc. (NYSE:ZTS)’s share price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $52.43 and last traded at $52.38, with a volume of 901,903 shares changing hands. The stock had previously closed at $51.98.

ZTS has been the topic of several research analyst reports. Guggenheim reiterated a “buy” rating and set a $60.00 price target on shares of Zoetis in a research report on Wednesday, May 4th. Goldman Sachs Group Inc. cut Zoetis from a “neutral” rating to a “sell” rating and lifted their price target for the company from $46.00 to $48.00 in a research report on Friday, May 6th. Jefferies Group reiterated a “buy” rating on shares of Zoetis in a research report on Sunday, May 8th. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $53.00 price target on the stock in a research report on Monday, May 9th. Finally, Credit Suisse Group AG reiterated a “buy” rating on shares of Zoetis in a research report on Sunday, May 22nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $54.63.

The firm has a market capitalization of $25.79 billion and a price-to-earnings ratio of 40.57. The company has a 50 day moving average of $49.78 and a 200 day moving average of $46.14.

Zoetis (NYSE:ZTS) last announced its earnings results on Wednesday, August 3rd. The company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.44 by $0.05. The business earned $1.20 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same period in the previous year, the firm earned $0.43 earnings per share. The firm’s revenue was up 2.8% compared to the same quarter last year. Equities analysts expect that Zoetis Inc. will post $1.90 EPS for the current year.

Several hedge funds and institutional investors have made changes to their positions in ZTS. Calvert Investment Management Inc. increased its position in shares of Zoetis by 24.8% in the fourth quarter. Calvert Investment Management Inc. now owns 28,411 shares of the company’s stock valued at $1,361,000 after buying an additional 5,639 shares during the last quarter. Greenwood Capital Associates LLC purchased a new position in Zoetis during the fourth quarter valued at about $1,532,000. King Luther Capital Management Corp purchased a new position in Zoetis during the fourth quarter valued at about $6,256,000. KBC Group NV increased its position in Zoetis by 19.5% in the fourth quarter. KBC Group NV now owns 226,507 shares of the company’s stock valued at $10,854,000 after buying an additional 37,018 shares in the last quarter. Finally, BlackRock Advisors LLC increased its position in Zoetis by 8.7% in the fourth quarter. BlackRock Advisors LLC now owns 2,523,641 shares of the company’s stock valued at $120,932,000 after buying an additional 202,029 shares in the last quarter.

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.